Cargando…
A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre
The increased use of immune checkpoint inhibitors across cancer programs has created the need for standardized patient assessment, education, monitoring, and management of immune-related adverse events (irAEs). At William Osler Health System in Brampton, Ontario, a practical step-wise approach detai...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870472/ https://www.ncbi.nlm.nih.gov/pubmed/35200573 http://dx.doi.org/10.3390/curroncol29020074 |
_version_ | 1784656759188619264 |
---|---|
author | Cheema, Parneet K. Iafolla, Marco A. J. Nematollahi, Massey Berco, FeRevelyn Kaushik, Deepanjali Matthews, Priscilla Raskin, William R. Perdrizet, Kirstin A. Dudani, Shaan Husain, Juhi Balcewicz, Margaret Kuruvilla, Philip G. Reingold, Stephen M. Conter, Henry J. |
author_facet | Cheema, Parneet K. Iafolla, Marco A. J. Nematollahi, Massey Berco, FeRevelyn Kaushik, Deepanjali Matthews, Priscilla Raskin, William R. Perdrizet, Kirstin A. Dudani, Shaan Husain, Juhi Balcewicz, Margaret Kuruvilla, Philip G. Reingold, Stephen M. Conter, Henry J. |
author_sort | Cheema, Parneet K. |
collection | PubMed |
description | The increased use of immune checkpoint inhibitors across cancer programs has created the need for standardized patient assessment, education, monitoring, and management of immune-related adverse events (irAEs). At William Osler Health System in Brampton, Ontario, a practical step-wise approach detailing the implementation of cancer immunotherapy in routine practice was developed. The approach focuses on four key steps: (1) identification of patient educators; (2) development of patient education materials; (3) development of patient monitoring tools; (4) involvement and education of multidisciplinary teams. Here, we provide an in-depth description of what was included in each step and how we integrated the different elements of the program. For each step, resources, tools, and materials that may be useful for patients, healthcare providers, and multidisciplinary teams were developed or modified based on existing materials. At our centre, the program led to improved patient comprehension of irAEs, the ability to act on symptoms (patient self-efficacy), and low rates of emergency room visits at first presentation for irAEs. We recognize that centres may need to tailor the approaches to their institutional policies and encourage centres to adapt and modify the forms and tools according to their needs and requirements. |
format | Online Article Text |
id | pubmed-8870472 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88704722022-02-25 A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre Cheema, Parneet K. Iafolla, Marco A. J. Nematollahi, Massey Berco, FeRevelyn Kaushik, Deepanjali Matthews, Priscilla Raskin, William R. Perdrizet, Kirstin A. Dudani, Shaan Husain, Juhi Balcewicz, Margaret Kuruvilla, Philip G. Reingold, Stephen M. Conter, Henry J. Curr Oncol Guidelines The increased use of immune checkpoint inhibitors across cancer programs has created the need for standardized patient assessment, education, monitoring, and management of immune-related adverse events (irAEs). At William Osler Health System in Brampton, Ontario, a practical step-wise approach detailing the implementation of cancer immunotherapy in routine practice was developed. The approach focuses on four key steps: (1) identification of patient educators; (2) development of patient education materials; (3) development of patient monitoring tools; (4) involvement and education of multidisciplinary teams. Here, we provide an in-depth description of what was included in each step and how we integrated the different elements of the program. For each step, resources, tools, and materials that may be useful for patients, healthcare providers, and multidisciplinary teams were developed or modified based on existing materials. At our centre, the program led to improved patient comprehension of irAEs, the ability to act on symptoms (patient self-efficacy), and low rates of emergency room visits at first presentation for irAEs. We recognize that centres may need to tailor the approaches to their institutional policies and encourage centres to adapt and modify the forms and tools according to their needs and requirements. MDPI 2022-02-04 /pmc/articles/PMC8870472/ /pubmed/35200573 http://dx.doi.org/10.3390/curroncol29020074 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Guidelines Cheema, Parneet K. Iafolla, Marco A. J. Nematollahi, Massey Berco, FeRevelyn Kaushik, Deepanjali Matthews, Priscilla Raskin, William R. Perdrizet, Kirstin A. Dudani, Shaan Husain, Juhi Balcewicz, Margaret Kuruvilla, Philip G. Reingold, Stephen M. Conter, Henry J. A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre |
title | A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre |
title_full | A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre |
title_fullStr | A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre |
title_full_unstemmed | A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre |
title_short | A Guide to Implementing Immune Checkpoint Inhibitors within a Cancer Program: Experience from a Large Canadian Community Centre |
title_sort | guide to implementing immune checkpoint inhibitors within a cancer program: experience from a large canadian community centre |
topic | Guidelines |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870472/ https://www.ncbi.nlm.nih.gov/pubmed/35200573 http://dx.doi.org/10.3390/curroncol29020074 |
work_keys_str_mv | AT cheemaparneetk aguidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre AT iafollamarcoaj aguidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre AT nematollahimassey aguidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre AT bercoferevelyn aguidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre AT kaushikdeepanjali aguidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre AT matthewspriscilla aguidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre AT raskinwilliamr aguidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre AT perdrizetkirstina aguidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre AT dudanishaan aguidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre AT husainjuhi aguidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre AT balcewiczmargaret aguidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre AT kuruvillaphilipg aguidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre AT reingoldstephenm aguidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre AT conterhenryj aguidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre AT cheemaparneetk guidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre AT iafollamarcoaj guidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre AT nematollahimassey guidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre AT bercoferevelyn guidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre AT kaushikdeepanjali guidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre AT matthewspriscilla guidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre AT raskinwilliamr guidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre AT perdrizetkirstina guidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre AT dudanishaan guidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre AT husainjuhi guidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre AT balcewiczmargaret guidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre AT kuruvillaphilipg guidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre AT reingoldstephenm guidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre AT conterhenryj guidetoimplementingimmunecheckpointinhibitorswithinacancerprogramexperiencefromalargecanadiancommunitycentre |